Nuvectis Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	18.53	19.13	19.99	5.74	-
Cash & Short-Term Investments	18.53	19.13	19.99	5.74	-
Cash Growth	-3.10%	-4.34%	248.19%	-	-
Other Current Assets	0.07	0.06	0.41	0.09	-
Total Current Assets	18.61	19.19	20.41	5.83	-
Long-Term Deferred Charges	-	-	-	0.82	-
Total Assets	18.61	19.19	20.41	6.66	-
Accounts Payable	2.5	2.77	2.91	1.06	0.01
Accrued Expenses	6.4	4.21	2.83	0.54	-
Other Current Liabilities	-	-	0.45	0.82	-
Total Current Liabilities	8.89	6.98	6.19	2.42	0.01
Total Liabilities	8.89	6.98	6.19	2.42	0.01
Additional Paid-In Capital	82.96	66.45	46.2	1.89	-
Retained Earnings	-73.25	-54.25	-31.99	-12.9	-0.01
Total Common Equity	9.71	12.2	14.22	-11.01	-0.01
Shareholders' Equity	9.71	12.2	14.22	4.24	-0.01
Total Liabilities & Equity	18.61	19.19	20.41	6.66	-
Net Cash (Debt)	18.53	19.13	19.99	5.74	-
Net Cash Growth	-3.10%	-4.34%	248.19%	-	-
Net Cash Per Share	1.08	1.23	1.58	1.35	-
Filing Date Shares Outstanding	23.39	17.77	14.75	12.72	3.9
Total Common Shares Outstanding	19.5	17.42	14.64	4.51	3.9
Working Capital	9.71	12.2	14.22	3.41	-0.01
Book Value Per Share	0.50	0.70	0.97	-2.44	-0.00
Tangible Book Value	9.71	12.2	14.22	-11.01	-0.01
Tangible Book Value Per Share	0.50	0.70	0.97	-2.44	-0.00

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q